A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer
Inclusion Criteria:
- Histologically confirmed NSCLC and Stage 3b or 4 NSCLC (Phase 1 only), Stage 3b or 4
NSCLC (Phase 2 only)
- Documented progressive disease following a prior RECIST response to monotherapy with
erlotinib OR documented progressive disease following stable disease of at least 6
months on monotherapy with erlotinib (Phase 2 only)
- Must have tolerated erlotinib at the maximal dose that will be administered in Phase
2 only (or at a higher dose) for a minimum of 6 weeks
- Measurable disease per RECIST (Phase 2 only)
- At least 18 years old
- ECOG performance status of 0 or 1
- Adequate organ and marrow function
- Sexually active subjects must agree to use medically accepted methods of
contraception during the course of the study and for 3 months following
discontinuation of study treatment (excluding women who are not of child bearing
potential and men who have been sterilized).
- Female subjects of childbearing potential must have a negative pregnancy test at
enrollment
- No other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ
of the cervix or malignancy diagnosed ≥ 2 years previously, and currently with no
evidence of disease).
- Capable of understanding and complying with the protocol, and written informed
consent
Exclusion Criteria:
- Received anti-cancer treatment within 4 weeks, except erlotinib, prior to first dose
(Phase 1 only)
- In Phase 2 only: the subject has received:
- Small molecule inhibitors of VEGFR2/KDR OR
- An investigational anti-cancer agent within 4 weeks of the first dose of study
drug OR
- An investigational agent that targets EGF or EGFR at any time OR
- An approved agent that targets EGF or EGFR (with the exception of erlotinib and
gefitinib) at any time unless approved by Exelixis OR
- Anti-cancer therapy within 4 weeks (with the exception of gefitinib and
erlotinib) of the first dose of study drug OR
- Prior therapy with a c-Met inhibitor
- Not recovered to NCI CTCAE v.3 Grade ≤1 from clinically significant adverse events
due to antineoplastic agents, investigational drugs, or other medications
administered prior to study enrollment
- Symptomatic or uncontrolled brain metastases requiring current treatment, including
steroids and anticonvulsants
- History of significant hematemesis or recent history of hemoptysis
- Presence of cavitation, central lesion, or lesion abutting a major blood vessel
- Intercurrent illness such as hypertension or cardiac arrhythmias or recent history of
significant disease such as congestive heart failure
- Pregnant or breastfeeding
- Active bacterial or viral infection requiring systemic treatment
- Allergy or hypersensitivity to components of either the XL184 or erlotinib
formulations
- Incapable of understanding and complying with the protocol or unable to provide
informed consent
- History of idiopathic pulmonary fibrosis or interstitial lung disease